ReviewEuropean cardiology2023
The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease.
Review in European cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial.Journal of atherosclerosis and thrombosis · 2025Trial
- Inflammation in atherosclerosis: Drivers, mechanisms and therapies.Acta pharmaceutica Sinica. B · 2026Review
- Impact of cancer history on coronary calcification and clinical outcomes in intravascular ultrasound-guided percutaneous coronary intervention.Coronary artery disease · 2026Article
- Modulation and Reprogramming of Adipose Tissue Macrophages in Obesity.Biomolecules · 2026Review
- The effects of a body shape index and remnant cholesterol inflammatory index on incident cardiovascular diseases: insights from a nationwide cohort study.Lipids in health and disease · 2026Article
- Development and validation of the C-reactive protein-triglyceride-glucose index for predicting short- and long-term mortality in critically ill patients with coronary artery disease: a multicenter cohort study.Frontiers in cardiovascular medicine · 2026Article
- Establishment and evaluation of predictive model for acute heart failure after PCI in patients with STEMI.Frontiers in cardiovascular medicine · 2026Article
- Triglycerides, Glucose Metabolism, and Type 2 Diabetes.International journal of molecular sciences · 2025Review
- Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease.European journal of medical research · 2025Review
- Effect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics.Cell reports. Medicine · 2025Article
- Low awareness of lipid disorders amongst individuals despite their high prevalence.Irish journal of medical science · 2025Article
- Association Between Triglyceride/High-Density Lipoprotein Ratio and Incidence Risk of Heart Failure: A Population-Based Cohort Study.Journal of clinical medicine · 2025Article
- Efficient secretory expression, purification, and characterization of lipase in Pseudomonas aeruginosa M18, with multifunctional applications in diagnostics.World journal of microbiology & biotechnology · 2025Article
- Diagnostic value of triglyceride-rich lipoprotein cholesterol for coronary artery lesions and its predictive significance for long-term prognosis in elderly patients with coronary heart disease.Frontiers in cardiovascular medicine · 2025Article
- Dysregulated cellular metabolism drives atherosclerotic plaque progression: a multi-cellular perspective.Frontiers in cardiovascular medicine · 2025Review
- Research progress on the mechanism and markers of metabolic disorders in the occurrence and development of cognitive dysfunction after ischemic stroke.Frontiers in endocrinology · 2025Review
- ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting.Frontiers in endocrinology · 2025Review
- Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study.Cardiovascular diabetology · 2024Observational
- The prognostic role of remnant cholesterol in Asian menopausal women received percutaneous coronary intervention with acute coronary syndrome.Lipids in health and disease · 2024Article
- Assessment of Various Insulin Resistance Surrogate Indices in Thai People with Type 2 Diabetes Mellitus.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the world's leading cause of death. ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia, hypertension, diabetes and heightened systemic inflammatory tone, among others. LDL cholesterol is one of the most well-studied and established mediators targeted for primary and secondary prevention of ASCVD. However, despite the strength of evidence supporting LDL cholesterol reduction by multiple management strategies, ASCVD events can still recur, even in patients whose LDL cholesterol has been very aggressively reduced. Hypertriglyceridaemia and elevated levels of triglyceride-rich lipoproteins (TRLs) may be key contributors to ASCVD residual risk. Several observational and genetic epidemiological studies have highlighted the causal role of triglycerides within the TRLs and/or their remnant cholesterol in the development and progression of ASCVD. TRLs consist of intestinally derived chylomicrons and hepatically synthesised very LDL. Lifestyle modification has been considered the first line intervention for managing hypertriglyceridaemia. Multiple novel targeted therapies are in development, and have shown efficacy in the preclinical and clinical phases of study in managing hypertriglyceridaemia and elevated TRLs. This comprehensive review provides an overview of the biology, pathogenicity, epidemiology, and genetics of triglycerides and TRLs, and how they impact the risk for ASCVD. In addition, we provide a summary of currently available and novel emerging triglyceride-lowering therapies in development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.